2025-09-06 - Analysis Report
Okay, here's a report on Hims & Hers Health Inc. (HIMS), incorporating the data you provided.

**Hims & Hers Health Inc. (HIMS) Analysis**

**Company Overview:** Hims & Hers Health Inc. is a telehealth company offering personalized health and wellness solutions directly to consumers.

**1. Performance vs. S&P 500 (VOO):**

*   **HIMS Cumulative Return:** 173.03%
*   **VOO Cumulative Return:** 69.90%
*   **Absolute Divergence:** 99.7 (HIMS outperformed VOO significantly)
*   **Relative Divergence:** 49.9 (Indicates HIMS's outperformance is in the middle of its historical range relative to VOO)
*   **Analysis:** HIMS has substantially outperformed the S&P 500.

**Alpha/Beta Analysis (Periodical):**

| Year       | CAGR    | MDD    | Alpha  | Beta  | Cap(B) |
|------------|---------|--------|--------|-------|--------|
| 2019-2021  | -46.0%  | 51.0%  | -84.0% | -0.0  | 1.5    |
| 2020-2022  | -15.0%  | 72.1%  | -17.0% | -0.0  | 1.4    |
| 2021-2023  | -51.0%  | 72.1%  | -69.0% | -0.1  | 2.0    |
| 2022-2024  | 127.0%  | 78.4%  | 101.0% | -0.1  | 5.5    |
| 2023-2025  | 168.0%  | 80.7%  | 115.0% | -0.1  | 10.9   |

*   **Analysis:**
    *   **CAGR:** Recent periods (2022-2024 and 2023-2025) show significant growth. The earlier periods show negative growth.
    *   **MDD:** High Maximum Drawdown (MDD) indicates significant volatility.
    *   **Alpha:** Recent periods (2022-2024 and 2023-2025) show very strong alpha, indicating outperformance relative to a benchmark.  The prior periods show negative alpha.
    *   **Beta:** Beta is consistently negative, suggesting an inverse correlation to the market (though the magnitude is small).
    *   **Cap:** Market Cap has grown significantly over the analysis period.

**2. Recent Stock Price Movement:**

*   **Current Price:** $48.41
*   **Previous Close:** $48.11
*   **Change:** 0.62%
*   **5-day Moving Average:** $45.67
*   **20-day Moving Average:** $45.77
*   **60-day Moving Average:** $50.86

*   **Analysis:** The stock price is above both the 5-day and 20-day moving averages, but below the 60-day moving average, suggesting a mixed short-term trend.  The recent price increase reflects positively and a potential for further upward movement.

**3. Market Risk Indicators and Signals:**

*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI:** 55.81 (Neutral, neither overbought nor oversold)
*   **PPO:** 1.19 (Positive, indicates upward price momentum)
*   **Hybrid Signal:** cash_3%_Buy 80% of cash (473 shares - Caution - MRI:0.33)
*   **Recent Relative Divergence Change (20-day):** 0.7 (Positive, Short-term increase)
*   **Expected Return:** -13.8% (Long-term relative underperformance vs. S&P 500 if investing now).

*   **Analysis:**  The MRI indicates a low-risk environment. The RSI is neutral.  The positive PPO and short-term divergence suggest recent upward momentum. The hybrid signal suggests a cautious buy. The expected return is concerning, signaling possible future underperformance compared to the S&P 500. Given the modest price change (0.62%), no extreme volatility issues appear to be in play currently.

**4. Recent News & Significant Events:**

*   **Positive News:**
    *   Court rejected Eli Lilly lawsuit.
    *   Reported a 1,600% Share Price Increase in Less Than 4 Years.
    *   Gains after court rejects Eli Lilly’s case.
*   **Trending Stock:** Listed as a Trending Stock.

*   **Analysis:** The recent news is predominantly positive, especially the dismissal of the lawsuit and the reported share price growth.

**4-2. Analyst Opinions:**

*   **Mean Analyst Rating:** Not Available
*   **Number of Opinions:** 11
*   **Target Price (avg/high/low):** $49.45 / $85.00 / $28.00

*   **Analysis:** The average target price ($49.45) is slightly above the current price, suggesting potential upside according to analysts.  However, there is a wide range in target prices ($28 to $85), indicating uncertainty in analyst estimates.

**5. Recent Earnings Analysis:**

| 날짜         | EPS  | 매출       |
|--------------|------|------------|
| 2025-08-04   | 0.19 | 0.54 B$    |
| 2025-05-05   | 0.22 | 0.59 B$    |
| 2024-11-04   | 0.35 | 0.40 B$    |
| 2024-08-05   | 0.06 | 0.32 B$    |
| 2025-08-04   | 0.06 | 0.32 B$    |

*   **Analysis:**
    *   Revenue has generally been increasing, with a notable jump in the most recent quarters.
    *   EPS shows volatility and a fluctuating pattern.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-06-30   | $0.54B  | 76.39%        |
| 2025-03-31   | $0.59B  | 73.50%        |
| 2024-12-31   | $0.48B  | 76.81%        |
| 2024-09-30   | $0.40B  | 79.16%        |
| 2024-06-30   | $0.32B  | 81.30%        |

**Capital and Profitability:**

| Quarter      | Equity  | ROE    |
|--------------|---------|--------|
| 2025-06-30   | $0.56B  | 7.55%  |
| 2025-03-31   | $0.55B  | 9.01%  |
| 2024-12-31   | $0.48B  | 5.46%  |
| 2024-09-30   | $0.44B  | 17.18% |
| 2024-06-30   | $0.36B  | 3.67%  |

*   **Analysis:**
    *   Revenue has been steadily increasing.
    *   Profit Margins are very high.
    *   Equity is growing.
    *   ROE has fluctuated, but recently declined.

**7. Overall Assessment:**

Hims & Hers has demonstrated significant growth and outperformance relative to the S&P 500, particularly in recent periods. Recent positive news related to legal victories and market recognition further supports the stock's upward momentum. The low MRI is a positive sign. However, a very high MDD indicates significant volatility. Furthermore, the recent expected return data raises a red flag. And the negative Beta could mean less correlation of movement to the general market than comparable stocks. While analyst target prices suggest potential upside, the range is wide, indicating uncertainty. In conclusion, HIMS presents a mixed picture: high growth potential with corresponding high risk and volatility. Potential investors should carefully consider their risk tolerance and conduct further due diligence.
